SCHEMBL411822

SCHEMBL411822

OC(COc1ccccc1)Cn1c2ccccc2c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 1.00
MAPT P10636 6/20 1.00
RECQL P46063 2/20 1.00
MEN1 O00255 4/20 0.78
KMT2A Q03164 4/20 0.78
KDM4E B2RXH2 3/20 0.78
CYP2D6 P10635 3/20 0.78
CYP1A2 P05177 2/20 0.78
CYP3A4 P08684 2/20 0.78
CYP2C9 P11712 2/20 0.78
CYP2C19 P33261 2/20 0.78
NPSR1 Q6W5P4 2/20 0.78
L3MBTL1 Q9Y468 2/20 0.66
BACE1 P56817 2/20 0.66
HTT P42858 3/20 0.65
HPGD P15428 2/20 0.65
GAA P10253 2/20 0.65
SLC5A2 P31639 1/20 0.60
ALOX15 P16050 1/20 0.59
HSD17B10 Q99714 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411339 0.88 LMNA (0.80) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL14701105 0.88 MAPT (0.78) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL19547484 0.87 MAPT (0.77) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL14689733 0.86 LMNA (0.74) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL18925969 0.84 MAPT (0.70) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL14689232 0.83 LMNA (0.69) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL407015 0.83 MAPT (0.70) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL407016 0.83 MAPT (0.70) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL409179 0.83 MAPT (0.70) LMNAMAPTRECQLMEN1KMT2A
SCHEMBL18930636 0.82 LMNA (0.67) LMNAMAPTRECQLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
EP-2590647-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2017-11-08 EP claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
US-20160206594-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-21 US claimed
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-10-15 US claimed
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 EP claimed
US-20150057301-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-26 US claimed
US-20140343018-A1 Anti-depression Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2014-11-20 US claimed
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP claimed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US claimed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BDNF, GAP43, DCX LMNA 993/4885MAPT 578/4885RECQL 4381/4885
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX LMNA 174/4885MAPT 136/4885RECQL 2885/4885
US-20160206594-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF LMNA 654/4885MAPT 559/4885RECQL 4446/4885
US-20150057301-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF LMNA 521/4885MAPT 620/4885RECQL 4471/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX LMNA 174/4885MAPT 136/4885RECQL 2885/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF LMNA 654/4885MAPT 559/4885RECQL 4446/4885
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF LMNA 654/4885MAPT 559/4885RECQL 4446/4885
US-20140343018-A1 Anti-depression Compounds BDNF, DCX, GAP43 LMNA 523/4885MAPT 142/4885RECQL 2553/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX LMNA 174/4885MAPT 136/4885RECQL 2885/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF LMNA 628/4885MAPT 571/4885RECQL 4503/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF LMNA 654/4885MAPT 559/4885RECQL 4446/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 LMNA 523/4885MAPT 142/4885RECQL 2553/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 LMNA 523/4885MAPT 142/4885RECQL 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.